semaglutide select Semaglutide: The Drug of Today and a Steppingstone to Tomorrow glp-1 receptor agonist kidney outcomes

Medullary thyroid cancer and C-cell hyperplasia remain a boxed warning for both medications based on animal studies, not human evidence

Were giving you 90 days notice to figure out what you want to do. From 2025 to 2026, 12 million people were on plans that dropped coverage for Zepbound and 12 million had plans that dropped Wegovy, another GLP-1, according to research by GoodRx, a website that helps patients find discounts on prescription drugs

Crucially, there is no established evidence base for efficacy at low doses specifically for inflammation, and the dose-response relationship for anti-inflammatory effects is unknown

Your provider sets realistic expectations and adjusts your plan as you go

This creates a 5mg/mL concentration where a 1mg starting dose requires 20 units (easy to read on any syringe) and a 2mg dose requires 40 units (clean, precise marking)

doi: 10.2174/1381612821666150909095916 40